Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis

The Lancet Diabetes and Endocrinology

Volumn 4, Issue 10, 2016, Pages 840-849

  Nambi, Vijay ^a   Ballantyne, Christie M ^a   Hoogeveen, Ron C ^a   Agarwal, Sunil K ^a   Panagiotakos, Demosthenes B ^a   Wannamethee, S Goya ^a   Whincup, Peter H ^a   Kiechl, Stefan ^a   Willeit, Johann ^a   Schett, Georg ^a   Santer, Peter ^a   Willeit, Peter ^a   Casas, Juan Pablo ^a   Lawlor, Debbie A ^a   DeFilippi, Christopher ^a   Kronmal, Richard A ^a   Psaty, Bruce M ^a   Cushman, Mary ^a   Nordestgaard, Børge G ^a   Olsen, Michael Hecht ^a   Jørgensen, Torben ^a   de Lemos, James A ^a   McGuire, Darren K ^a   Das, Sandeep R ^a   Drazner, Mark H ^a   Salomaa, Veikko ^a   Vartiainen, Erkki ^a   Harald, Kennet ^a   Zeller, Tanja ^a   Levy, Daniel ^a   Ninomiya, Toshiharu ^a   Hata, Jun ^a   Kiyohara, Yutaka ^a   Kauhanen, Jussi ^a   Salonen, Jukka T ^a   Laukkanen, Jari A ^a   Tuomainen, Tomi Pekka ^a   Ruskoaho, Heikki ^a   Kistorp, Caroline N ^a   Raymond, Ilan ^a   Mueller, Thomas ^a   Dieplinger, Benjamin ^a   Haltmayer, Meinhard ^a   Melander, Olle ^a   Heckbert, Susan R ^a   Lima, João A ^a   Luchner, Andreas ^a   Stark, Klaus ^a   Heid, Iris M ^a   Peters, Annette ^a   Andersson, Jonas ^a   Jansson, Jan Håkan ^a   Wennberg, Patrik ^a   Rubattu, Speranza ^a   Volpe, Massimo ^a   Strazzullo, Pasquale ^a   Lind, Lars ^a   Venge, Per ^a   Lindahl, Bertil ^a   de Boer, Rudolf A ^a   Bakker, Stephan J L ^a   Gansevoort, Ron T ^a   Kee, Frank ^a   Evans, Alun ^a   Yarnell, John W G ^a   Trompet, Stella ^a   Jukema, J Wouter ^a   Stott, David J ^a   de Craen, Anton J M ^a   Rosenberg, Jens ^a   Hildebrandt, Per R ^a   Gustafsson, Finn ^a   Schou, Morten ^a   Daniels, Lori B ^a   Barrett Connor, Elizabeth ^a   Maisel, Alan S ^a   Judd, Suzanne ^a   Safford, Monika M ^a   Howard, Virginia J ^a   Zakai, Neil A ^a   Gudnason, Vilmundur ^a   Aspelund, Thor ^a   Eiriksdottir, Gudny ^a   Agnarsson, Uggi ^a   Andresdottir, Margret B ^a   Kavousi, Maryam ^a   Hofman, Albert ^a   Ligthart, Symen ^a   van den Meiracker, Anton H ^a   Franco, Oscar H ^a   Dehghan, Abbas ^a   van Rooij, Frank J A ^a   Ikram, M Arfan ^a   Kizer, Jorge R ^a   Best, Lyle G ^a   Devereux, Richard B ^a   Umans, Jason G ^a   Ärnlöv, Johan ^a   Zethelius, Björn ^a   Lannfelt, Lars ^a   Giedraitis, Vilmantas ^a   Cook, Nancy R ^a   Manson, JoAnn E ^a   Everett, Brendan M ^a   Ridker, Paul M ^a   Pradhan, Aruna D ^a   Sattar, Naveed ^a   Ford, Ian ^a   Packard, Chris J ^a   Welsh, Paul ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

AGE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONCENTRATION (PARAMETERS); DEVELOPED COUNTRY; DIABETES MELLITUS; EVIDENCE BASED PRACTICE; FOLLOW UP; HEART FAILURE; HIGH INCOME COUNTRY; HUMAN; ISCHEMIC HEART DISEASE; MEDICAL HISTORY; META ANALYSIS (TOPIC); PREDICTION; PREDICTIVE VALUE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SMOKING HABIT; SYSTEMATIC REVIEW (TOPIC); SYSTOLIC BLOOD PRESSURE; AGED; BLOOD; FEMALE; MALE; META ANALYSIS; MIDDLE AGED;

AGED; BIOMARKERS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 84990052413     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(16)30196-6     Document Type: Article

References (62)

1. Goff, DC Jr, Lloyd-Jones, DM, Bennett, G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk. Circulation 129:25 suppl 2 (2014), S49–S73.
2. Piepoli, MF, Hoes, AW, Agewall, S, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 37 (2016), 2315–2381.
3. Greenland, P, Alpert, JS, Beller, GA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults. Circulation 122 (2010), e584–e636.
4. 4 National Institute for Health and Care Excellence. Cardiovascular disease: risk assessment and reduction, including lipid modification, 2014, National Institute for Health and Care Excellence, London.
5. George, J, Rapsomaniki, E, Pujades-Rodriguez, M, et al. How does cardiovascular disease first present in women and men? Incidence of 12 cardiovascular diseases in a contemporary cohort of 1 937 360 people. Circulation 132 (2015), 1320–1328.
6. Law, MR, Morris, JK, Wald, NJ, Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ, 338, 2009, b1665.
7. Preiss, D, Campbell, RT, Murray, HM, et al. The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. Eur Heart J 36 (2015), 1536–1546.
8. Yancy, CW, Jessup, M, Bozkurt, B, et al. 2013 ACCF/AHA guideline for the management of heart failure. J Am Coll Cardiol 62 (2013), e147–e239.
9. McMurray, JJ, Adamopoulos, S, Anker, SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J 33 (2012), 1787–1847.
10. Levin, ER, Gardner, DG, Samson, WK, Natriuretic peptides. N Engl J Med 339 (1998), 321–328.
11. Di Angelantonio, E, Chowdhury, R, Sarwar, N, et al. B-type natriuretic peptides and cardiovascular risk. Circulation 120 (2009), 2177–2187.
12. Sattar, N, Welsh, P, Sarwar, N, et al. NT-proBNP is associated with coronary heart disease risk in healthy older women but fails to enhance prediction beyond established risk factors: results from the British Women's Heart and Health Study. Atherosclerosis 209 (2010), 295–299.
13. Melander, O, Newton-Cheh, C, Almgren, P, et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA 302 (2009), 49–57.
14. Rutten, JH, Mattace-Raso, FU, Steyerberg, EW, et al. Amino-terminal pro-B-type natriuretic peptide improves cardiovascular and cerebrovascular risk prediction in the population: the Rotterdam Study. Hypertension 55 (2010), 785–791.
15. Folsom, AR, Nambi, V, Bell, EJ, et al. Troponin T, N-terminal pro-B-type natriuretic peptide, and incidence of stroke: the Atherosclerosis Risk in Communities Study. Stroke 44 (2013), 961–967.
16. Choi, EY, Bahrami, H, Wu, CO, et al. N-terminal pro-B-type natriuretic peptide, left ventricular mass, and incident heart failure: multi-ethnic study of atherosclerosis. Circ Heart Fail 5 (2012), 727–734.
17. Stewart, LA, Clarke, M, Rovers, M, Preferred reporting items for a systematic review and meta-analysis of individual participant data: the PRISMA-IPD statement. JAMA 313 (2015), 1657–1665.
18. Thompson, S, Kaptoge, S, White, I, et al. Statistical methods for the time-to-event analysis of individual participant data from multiple epidemiological studies. Int J Epidemiol 39 (2010), 1345–1359.
19. Prentice, RL, A case-cohort design for epidemiologic cohort studies and disease prevention trials. Biometrika 73 (1986), 1–11.
20. Higgins, JP, Thompson, SG, Quantifying heterogeneity in a meta-analysis. Stat Med 21 (2002), 1539–1558.
21. Pennells, L, Kaptoge, S, White, IR, Thompson, SG, Wood, AM, for the Emerging Risk Factors Collaboration. Assessing risk prediction models using individual participant data from multiple studies. Am J Epidemiol 179 (2014), 621–632.
22. Sanderson, J, Thompson, SG, White, IR, Aspelund, T, Pennells, L, Derivation and assessment of risk prediction models using case-cohort data. BMC Med Res Methodol, 13, 2013, 113.
23. Jónsdóttir, LS, Sigfússon, N, Gudnason, V, Sigvaldason, H, Thorgeirsson, G, Do lipids, blood pressure, diabetes, and smoking confer equal risk of myocardial infarction in women as in men? The Reykjavik Study. J Cardiovasc Risk 9 (2002), 67–76.
24. Hallmans, G, Agren, A, Johansson, G, et al. Cardiovascular disease and diabetes in the Northern Sweden Health and Disease Study Cohort—evaluation of risk factors and their interactions. Scand J Public Health Suppl 61 (2003), 18–24.
25. Willeit, P, Kiechl, S, Kronenberg, F, et al. Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study. J Am Coll Cardiol 64 (2014), 851–860.
26. Osler, M, Linneberg, A, Glümer, C, Jørgensen, T, The cohorts at the Research Centre for Prevention and Health, formerly ‘The Glostrup Population Studies’. Int J Epidemiol 40 (2011), 602–610.
27. Kara, K, Lehmann, N, Neumann, T, et al. NT-proBNP is superior to BNP for predicting first cardiovascular events in the general population: the Heinz Nixdorf Recall Study. Int J Cardiol 183 (2015), 155–161.
28. de Lemos, JA, Drazner, MH, Omland, T, et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA 304 (2010), 2503–2512.
29. Blankenberg, S, Zeller, T, Saarela, O, et al. Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project. Circulation 121 (2010), 2388–2397.
30. Wang, TJ, Larson, MG, Levy, D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 350 (2004), 655–663.
31. Kistorp, C, Raymond, I, Pedersen, F, Gustafsson, F, Faber, J, Hildebrandt, P, N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 293 (2005), 1609–1616.
32. Luchner, A, Behrens, G, Stritzke, J, et al. Long-term pattern of brain natriuretic peptide and N-terminal pro brain natriuretic peptide and its determinants in the general population: contribution of age, gender, and cardiac and extra-cardiac factors. Eur J Heart Fail 15 (2013), 859–867.
33. Eggers, KM, Lindahl, B, Venge, P, Lind, L, B-type natriuretic peptides and their relation to cardiovascular structure and function in a population-based sample of subjects aged 70 years. Am J Cardiol 103 (2009), 1032–1038.
34. Kizer, JR, Krauser, DG, Rodeheffer, RJ, et al. Prognostic value of multiple biomarkers in American Indians free of clinically overt cardiovascular disease (from the Strong Heart Study). Am J Cardiol 104 (2009), 247–253.
35. Laukkanen, JA, Kurl, S, Ala-Kopsala, M, et al. Plasma N-terminal fragments of natriuretic propeptides predict the risk of cardiovascular events and mortality in middle-aged men. Eur Heart J 27 (2006), 1230–1237.
36. Fragopoulou, E, Panagiotakos, DB, Pitsavos, C, et al. N-terminal ProBNP distribution and correlations with biological characteristics in apparently healthy Greek population: ATTICA study. Angiology 61 (2010), 397–404.
37. Wannamethee, SG, Welsh, P, Lowe, GD, et al. N-terminal pro-brain natriuretic peptide is a more useful predictor of cardiovascular disease risk than C-reactive protein in older men with and without pre-existing cardiovascular disease. J Am Coll Cardiol 58 (2011), 56–64.
38. Patton, KK, Sotoodehnia, N, DeFilippi, C, Siscovick, DS, Gottdiener, JS, Kronmal, RA, N-terminal pro-B-type natriuretic peptide is associated with sudden cardiac death risk: the Cardiovascular Health Study. Heart Rhythm 8 (2011), 228–233.
39. Mogelvang, R, Goetze, JP, Schnohr, P, et al. Discriminating between cardiac and pulmonary dysfunction in the general population with dyspnea by plasma pro-B-type natriuretic peptide. J Am Coll Cardiol 50 (2007), 1694–1701.
40. Doi, Y, Ninomiya, T, Hata, J, et al. N-terminal pro-brain natriuretic peptide and risk of cardiovascular events in a Japanese community: the Hisayama study. Arterioscler Thromb Vasc Biol 31 (2011), 2997–3003.
41. Olsen, MH, Wachtell, K, Nielsen, OW, et al. N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy. J Hypertens 24 (2006), 1531–1539.
42. Barbato, A, Sciarretta, S, Marchitti, S, et al. Aminoterminal natriuretic peptides and cardiovascular risk in an Italian male adult cohort. Int J Cardiol 152 (2011), 245–246.
43. Linssen, GC, Bakker, SJ, Voors, AA, et al. N-terminal pro-B-type natriuretic peptide is an independent predictor of cardiovascular morbidity and mortality in the general population. Eur Heart J 31 (2010), 120–127.
44. Poortvliet, RK, van Peet, PG, de Craen, AJ, et al. Risk stratification and treatment effect of statins in secondary cardiovascular prevention in old age: additive value of N-terminal pro-B-type natriuretic peptide. Eur J Prev Cardiol 34 (2016), 1104–1113.
45. Rosenberg, J, Schou, M, Gustafsson, F, Badskjaer, J, Hildebrandt, P, Prognostic threshold levels of NT-proBNP testing in primary care. Eur Heart J 30 (2009), 66–73.
46. Daniels, LB, Laughlin, GA, Clopton, P, Maisel, AS, Barrett-Connor, E, Minimally elevated cardiac troponin T and elevated N-terminal pro-B-type natriuretic peptide predict mortality in older adults: results from the Rancho Bernardo Study. J Am Coll Cardiol 52 (2008), 450–459.
47. Howard, VJ, Cushman, M, Pulley, L, et al. The reasons for geographic and racial differences in stroke study: objectives and design. Neuroepidemiology 25 (2005), 135–143.
48. Zethelius, B, Berglund, L, Sundström, J, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 358 (2008), 2107–2116.
49. Everett, BM, Berger, JS, Manson, JE, Ridker, PM, Cook, NR, B-type natriuretic peptides improve cardiovascular disease risk prediction in a cohort of women. J Am Coll Cardiol 64 (2014), 1789–1797.
50. Everett, BM, Ridker, PM, Cook, NR, Pradhan, AD, Usefulness of B-type natriuretic peptides to predict cardiovascular events in women (from the Women's Health Study). Am J Cardiol 116 (2015), 532–537.
51. Welsh, P, Doolin, O, Willeit, P, et al. N-terminal pro-B-type natriuretic peptide and the prediction of primary cardiovascular events: results from 15-year follow-up of WOSCOPS. Eur Heart J 34 (2013), 443–450.
52. Patton, KK, Ellinor, PT, Heckbert, SR, et al. N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation. Circulation 120 (2009), 1768–1774.
53. Korngold, EC, Januzzi, JL, Gantzer, ML, Moorthy, MV, Cook, NR, Albert, CM, Amino-terminal pro-B-type natriuretic peptide and high-sensitivity C-reactive protein as predictors of sudden cardiac death among women. Circulation 119 (2009), 2868–2876.
54. Huelsmann, M, Neuhold, S, Resl, M, et al. PONTIAC (NT-proBNP Selected Prevention of Cardiac Events in a Population of Diabetic Patients Without a History of Cardiac Disease): a prospective randomized controlled trial. J Am Coll Cardiol 62 (2013), 1365–1372.
55. Brunner-La Rocca, HP, Eurlings, L, Richards, AM, et al. Which heart failure patients profit from natriuretic peptide guided therapy? A meta-analysis from individual patient data of randomized trials. Eur J Heart Fail 17 (2015), 1252–1261.
56. Ledwidge, M, Gallagher, J, Conlon, C, Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA 310 (2013), 66–74.
57. Ledwidge, MT, O'Connell, E, Gallagher, J, et al. Cost-effectiveness of natriuretic peptide-based screening and collaborative care: a report from the STOP-HF (St Vincent's Screening To Prevent Heart Failure) study. Eur J Heart Fail 17 (2015), 672–679.
58. Heidenreich, PA, Gubens, MA, Fonarow, GC, Konstam, MA, Stevenson, LW, Shekelle, PG, Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. J Am Coll Cardiol 43 (2004), 1019–1026.
59. Nielsen, OW, McDonagh, TA, Robb, SD, Dargie, HJ, Retrospective analysis of the cost-effectiveness of using plasmabrain natriuretic peptide inscreening for left ventricularsystolic dysfunction in the general population. J Am Coll Cardiol 41 (2003), 113–120.
60. Zanoni, P, Khetarpal, SA, Larach, DB, et al. Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease. Science 351 (2016), 1166–1171.
61. Due-Andersen, R, Pedersen-Bjergaard, U, Høi-Hansen, T, et al. NT-pro-BNP during hypoglycemia and hypoxemia in normal subjects: impact of renin-angiotensin system activity. J Appl Physiol 104 (2008), 1080–1085.
62. Goetze, JP, Gore, A, Moller, CH, Steinbrchel, DA, Rehfeld, JF, Nielsen, LB, Acute myocardial hypoxia increases BNP gene expression. FASEB J 18 (2004), 1928–1930.